文献速递头颈神经PETCTMR

头颈部神经内分泌肿瘤的生长抑素受体PET/CT/MRI

Somatostatin Receptor-PET/CT/MRI of Head and Neck Neuroendocrine Tumors.
PubMed 文献 · AJNR Am J Neuroradiol · 2023-07-13

比较生长抑素受体PET/MRI与单独增强MR对头颈部神经内分泌肿瘤的检出,并评估头顶至大腿成像的附加价值。25例中11例两者可比,7例PET/MRI显示更广泛病变,9例发现额外病灶;头顶至大腿成像17例中仅1例转移阳性。

要点

  • 生长抑素受体PET较单独增强MR可发现额外病灶并显示更广泛病变。
  • PET/MRI融合有助于肿瘤负荷的精细解剖定位,差异易于解决。
  • 头顶至大腿成像转移检出率低,但可发现偶发病灶。

核心结论

  • 生长抑素受体PET较单独增强MR检出更多额外病灶和更广泛病变,头顶至大腿成像转移发生率低;PET/MRI有助于头颈部神经内分泌肿瘤术前和放疗计划。

研究设计与样本

  • 给予64CU/68GA DOTATATE后行生长抑素受体PET/CT,采集范围限脑或头颈部,可选头顶至大腿成像,并与单独采集的增强MR融合;共30例患者成像,5例无生长抑素受体阳性病灶被排除,25例纳入分析。

关键影像表现/征象

  • 25例中11例生长抑素受体PET/MRI与MR表现可比。
  • 25例中7例生长抑素受体PET/MRI显示更广泛病变。
  • 25例中9例生长抑素受体PET/MRI识别出额外病灶。
  • 头顶至大腿成像17例中1例转移阳性、8例阴性、8例示偶发病灶。

诊断标准与关键数值

  • DOTATATE活性与MR比较分为可比、更广泛和/或显示额外病灶。
  • 头顶至大腿表现分为转移阳性、阴性或偶发。

临床应用与阅片要点

  • 生长抑素受体PET/MRI可提高头颈部神经内分泌肿瘤的病灶检出和范围评估。
  • 融合MRI有助于肿瘤负荷的解剖定位,对差异易于处理。
  • PET/MRI可能在术前和放疗计划中发挥作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Due to its high sensitivity, somatostatin receptor-PET may detect smaller lesions and more extensive disease than contrast-enhanced MR imaging, while the superior spatial resolution of MR imaging enables lesions to be accurately localized. We compared results of somatostatin receptor-PET/MRI with those of MR imaging alone and assessed the added value of vertex-to-thigh imaging for head and neck neuroendocrine tumors.

MATERIALS AND METHODS: Somatostatin receptor-PET/CT was acquired as limited brain or head and neck imaging, with optional vertex-to-thigh imaging, following administration of 64CU/68GA DOTATATE. Somatostatin receptor-PET was fused with separately acquired contrast-enhanced MR imaging. DOTATATE activity was classified as comparable, more extensive, and/or showing additional lesions compared with MR imaging. Vertex-to-thigh findings were classified as positive or negative for metastatic disease or incidental.

RESULTS: Thirty patients (with 13 meningiomas, 11 paragangliomas, 1 metastatic papillary thyroid carcinoma, 1 middle ear neuroendocrine adenoma, 1 external auditory canal mass, 1 pituitary carcinoma, 1 olfactory neuroblastoma, 1 orbital mass) were imaged. Five had no evidence of somatostatin receptor-positive lesions and were excluded. In 11/25, somatostatin receptor-PET/MRI and MR imaging were comparable. In 7/25, somatostatin receptor-PET/MRI showed more extensive disease, while in 9/25, somatostatin receptor-PET/MRI identified additional lesions. On vertex-to-thigh imaging, 1 of 17 patients was positive for metastatic disease, 8 of 17 were negative, and 8 of 17 demonstrated incidental findings.

CONCLUSIONS: Somatostatin receptor-PET detected additional lesions and more extensive disease than contrast-enhanced MR imaging alone, while vertex-to-thigh imaging showed a low incidence of metastatic disease. Somatostatin receptor-PET/MRI enabled superior anatomic delineation of tumor burden, while any discrepancies were readily addressed. Somatostatin receptor-PET/MRI has the potential to play an important role in presurgical and radiation therapy planning of head and neck neuroendocrine tumors.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Rini JN, Keir G, Caravella C, et al. Somatostatin Receptor-PET/CT/MRI of Head and Neck Neuroendocrine Tumors. AJNR Am J Neuroradiol. 2023. PMID: 37442593. doi:10.3174/ajnr.A7934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。